Tumor Suppressor Protein p53
"Tumor Suppressor Protein p53" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
| Descriptor ID |
D016159
|
| MeSH Number(s) |
D12.776.157.687.650 D12.776.260.820 D12.776.624.776.775 D12.776.660.720.650 D12.776.744.845
|
| Concept/Terms |
Tumor Suppressor Protein p53- Tumor Suppressor Protein p53
- p53 Antigen
- TP53 Protein
- TRP53 Protein
- p53 Tumor Suppressor Protein
- pp53 Phosphoprotein
- Phosphoprotein, pp53
- Cellular Tumor Antigen p53
- Oncoprotein p53
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Protein p53".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Protein p53".
This graph shows the total number of publications written about "Tumor Suppressor Protein p53" by people in this website by year, and whether "Tumor Suppressor Protein p53" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 11 | 6 | 17 |
| 1995 | 26 | 7 | 33 |
| 1996 | 23 | 11 | 34 |
| 1997 | 19 | 13 | 32 |
| 1998 | 30 | 35 | 65 |
| 1999 | 26 | 15 | 41 |
| 2000 | 31 | 21 | 52 |
| 2001 | 28 | 17 | 45 |
| 2002 | 34 | 27 | 61 |
| 2003 | 42 | 37 | 79 |
| 2004 | 30 | 26 | 56 |
| 2005 | 28 | 24 | 52 |
| 2006 | 35 | 29 | 64 |
| 2007 | 40 | 28 | 68 |
| 2008 | 28 | 20 | 48 |
| 2009 | 38 | 29 | 67 |
| 2010 | 39 | 31 | 70 |
| 2011 | 54 | 41 | 95 |
| 2012 | 36 | 33 | 69 |
| 2013 | 41 | 32 | 73 |
| 2014 | 41 | 32 | 73 |
| 2015 | 32 | 33 | 65 |
| 2016 | 38 | 32 | 70 |
| 2017 | 35 | 19 | 54 |
| 2018 | 34 | 21 | 55 |
| 2019 | 30 | 27 | 57 |
| 2020 | 23 | 31 | 54 |
| 2021 | 25 | 14 | 39 |
| 2022 | 12 | 32 | 44 |
| 2023 | 12 | 23 | 35 |
| 2024 | 17 | 12 | 29 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Suppressor Protein p53" by people in Profiles.
-
Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation. Cell Rep Med. 2024 Sep 17; 5(9):101711.
-
Trajectory of primordial follicle depletion is accelerated in obese mice in response to 7,12-dimethylbenz[a]anthracene exposure?. Biol Reprod. 2024 Aug 15; 111(2):483-495.
-
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2024 Oct; 189:138-145.
-
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug 05; 34(8):1283-1289.
-
Acute myeloid leukemia with mast cell differentiation is characterized by interstitial mast cells, complex karyotype, TP53 alterations and poor prognosis. Haematologica. 2024 08 01; 109(8):2711-2715.
-
TP53-associated early breast cancer: new observations from a large cohort. J Natl Cancer Inst. 2024 Aug 01; 116(8):1246-1254.
-
p53R172H and p53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional Mediator. Cancer Res Commun. 2024 Aug 01; 4(8):1991-2007.
-
ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma. Nat Commun. 2024 Jun 21; 15(1):5294.
-
Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant. J Hematol Oncol. 2024 Jun 18; 17(1):45.
-
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 Jun 18; 14(1):99.